Peripheral nerve injury is a well-recognized complication of surgery and anesthesia. However, overall incidence is less than 1% [1,2]. Most commonly affected nerves include the ulnar nerve, brachial plexus, and lumbosacral nerve root [2]. Postoperative facial nerve palsy as a complication of surgery and anesthesia has been documented in the literature, but it is a rare event [3]. The occurrence of any type of nerve injury as a postoperative complication is even less common in the pediatric population [2,3]. In this report, we describe a case of postoperative facial nerve palsy in a pediatric patient after a thoracotomy..
{"title":"Postoperative Facial Nerve Palsy in a Pediatric Patient.","authors":"Cindy B Yeoh, Kathleen J Lee, Luis E Tollinche","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Peripheral nerve injury is a well-recognized complication of surgery and anesthesia. However, overall incidence is less than 1% [1,2]. Most commonly affected nerves include the ulnar nerve, brachial plexus, and lumbosacral nerve root [2]. Postoperative facial nerve palsy as a complication of surgery and anesthesia has been documented in the literature, but it is a rare event [3]. The occurrence of any type of nerve injury as a postoperative complication is even less common in the pediatric population [2,3]. In this report, we describe a case of postoperative facial nerve palsy in a pediatric patient after a thoracotomy..</p>","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"4 5","pages":"36-38"},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802996/pdf/nihms-1727402.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39756427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jessica Kachmar, Caroline Albert, M. Dupuis, B. Imbeault, M. Vallée
Chronic kidney disease related mineral and bone disorders (CKD-MBD) cause significant morbidity and mortality. Guidelines for treatment and prevention of CKD-MBD have put focus on the treatment of secondary hyperparathyroidism in patients on hemodialysis by maintaining levels of parathormone (PTH) between 2 to 9 times the upper normal limit. However, levels of PTH are not always accurately correlated to the degree of bone remodeling, and some patients may suffer from hyperparathyroidism though their PTH levels are within the targets. Therefore, it is important to identify other bone markers that could help us adequately assess bone status in these patients, such as total alkaline phosphatase (TALP). In this case report, we describe a patient who suffered from poorly controlled hyperparathyroidism with very high levels of TALP despite having PTH levels within the targets. TALP could thus be an important bone marker and should be taken into consideration complementary to PTH when evaluating the bone status of a patient on dialysis.
{"title":"A case of secondary hyperparathyroidism in a patient on hemodialysis with parathormone levels within the targets and high total alkaline phosphatase","authors":"Jessica Kachmar, Caroline Albert, M. Dupuis, B. Imbeault, M. Vallée","doi":"10.15761/cmr.1000160","DOIUrl":"https://doi.org/10.15761/cmr.1000160","url":null,"abstract":"Chronic kidney disease related mineral and bone disorders (CKD-MBD) cause significant morbidity and mortality. Guidelines for treatment and prevention of CKD-MBD have put focus on the treatment of secondary hyperparathyroidism in patients on hemodialysis by maintaining levels of parathormone (PTH) between 2 to 9 times the upper normal limit. However, levels of PTH are not always accurately correlated to the degree of bone remodeling, and some patients may suffer from hyperparathyroidism though their PTH levels are within the targets. Therefore, it is important to identify other bone markers that could help us adequately assess bone status in these patients, such as total alkaline phosphatase (TALP). In this case report, we describe a patient who suffered from poorly controlled hyperparathyroidism with very high levels of TALP despite having PTH levels within the targets. TALP could thus be an important bone marker and should be taken into consideration complementary to PTH when evaluating the bone status of a patient on dialysis.","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"9 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91431081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Al Faker, Soukayna Kabbou, F. Marraha, Najlae Rahmani, Youness Benyamna, S. Gallouj
{"title":"A red tumor on the wrist. How useful is the dermoscopy: A case report","authors":"I. Al Faker, Soukayna Kabbou, F. Marraha, Najlae Rahmani, Youness Benyamna, S. Gallouj","doi":"10.15761/cmr.1000161","DOIUrl":"https://doi.org/10.15761/cmr.1000161","url":null,"abstract":"","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84693755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Asymptomatic arrythmias can result in adverse events including sudden cardiac death. Bradycardia is prevalent in active populations and can remain asymptomatic or become malignant. Pauses of six seconds in duration and syncope are the present criterion recommended for treatment. To the best of our knowledge, this is the first report supporting the use of intermittent ECG monitoring to identify an asymptomatic arrythmia associated with bradycardia which resulted in eventual placement of a pacemaker. Case presentation: The subject matter is a 31-year-old male recreational athlete who took chest and thumb ECGs intermittently throughout a 2-day period. On both days, abnormal rhythms were identified more than once in one of the leads. Follow up diagnostics included a 24-hour Holter revealing 6 isolated action potential durations, 2 isolated pre-ventricular contractions, 6 supraventricular ectopic beats, 2 ventricular ectopic beats, 28 bradycardic events and 18 pauses. At 6 month follow up, an insertable loop recorder identified 117 events with 112 pauses and 5 bradycardic events. Eleven of the pauses were of >6 seconds duration. A near syncope episode including symptoms of tunnel vision, nausea, diaphoresis and almost loss of consciousness resulted in hospitalization. The ECG at time of hospitalization showed normal sinus rhythm with ST-segment elevation and tall T waves. A dual chamber pacemaker was placed to prevent future episodes of syncope. Conclusion: The present case study highlights the need for additional objective criteria to identify patients requiring early management of asymptomatic bradycardia to prevent unnecessary hospitalization. Intermittent ECG assessment may provide an additional complimentary assessment which can regularly be utilized to monitor patients with asymptomatic arrythmia. De-conditioning may not be an option for treatment and waiting for syncope to occur leaves patients susceptible to sudden cardiac death or mortality as a result of uncontrollable circumstances at time of a near syncope episode. Development of additional monitoring processes and criteria for early pacemaker implantation are warranted.
{"title":"Early asymptomatic arrythmia detection using intermittent ECG in the diagnostic process – A case report","authors":"Krista G. Austin, R. Carter Iii, B. Reilly","doi":"10.15761/cmr.1000159","DOIUrl":"https://doi.org/10.15761/cmr.1000159","url":null,"abstract":"Introduction: Asymptomatic arrythmias can result in adverse events including sudden cardiac death. Bradycardia is prevalent in active populations and can remain asymptomatic or become malignant. Pauses of six seconds in duration and syncope are the present criterion recommended for treatment. To the best of our knowledge, this is the first report supporting the use of intermittent ECG monitoring to identify an asymptomatic arrythmia associated with bradycardia which resulted in eventual placement of a pacemaker. Case presentation: The subject matter is a 31-year-old male recreational athlete who took chest and thumb ECGs intermittently throughout a 2-day period. On both days, abnormal rhythms were identified more than once in one of the leads. Follow up diagnostics included a 24-hour Holter revealing 6 isolated action potential durations, 2 isolated pre-ventricular contractions, 6 supraventricular ectopic beats, 2 ventricular ectopic beats, 28 bradycardic events and 18 pauses. At 6 month follow up, an insertable loop recorder identified 117 events with 112 pauses and 5 bradycardic events. Eleven of the pauses were of >6 seconds duration. A near syncope episode including symptoms of tunnel vision, nausea, diaphoresis and almost loss of consciousness resulted in hospitalization. The ECG at time of hospitalization showed normal sinus rhythm with ST-segment elevation and tall T waves. A dual chamber pacemaker was placed to prevent future episodes of syncope. Conclusion: The present case study highlights the need for additional objective criteria to identify patients requiring early management of asymptomatic bradycardia to prevent unnecessary hospitalization. Intermittent ECG assessment may provide an additional complimentary assessment which can regularly be utilized to monitor patients with asymptomatic arrythmia. De-conditioning may not be an option for treatment and waiting for syncope to occur leaves patients susceptible to sudden cardiac death or mortality as a result of uncontrollable circumstances at time of a near syncope episode. Development of additional monitoring processes and criteria for early pacemaker implantation are warranted.","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88608217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cindy B Yeoh, Kathleen J Lee, Vanja Coric, Luis E Tollinche
The environmental debate on going green in the operating room (OR) has been a controversial topic for many years. Challengers of greening efforts cite various obstacles and arguments against these initiatives. However, ORs in the United States continue to generate a staggering amount of waste daily. In this article, we review major barriers to going green and highlight simple, yet effective greening strategies that anesthesia practices could adopt to reduce our carbon footprint.
{"title":"Simple Green Changes for Anesthesia Practices to Make a Difference.","authors":"Cindy B Yeoh, Kathleen J Lee, Vanja Coric, Luis E Tollinche","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The environmental debate on going green in the operating room (OR) has been a controversial topic for many years. Challengers of greening efforts cite various obstacles and arguments against these initiatives. However, ORs in the United States continue to generate a staggering amount of waste daily. In this article, we review major barriers to going green and highlight simple, yet effective greening strategies that anesthesia practices could adopt to reduce our carbon footprint.</p>","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"3 12","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808258/pdf/nihms-1647000.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38831256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Non-specific interstitial pneumonia (NSIP) is the second most common morphological and pathological pattern of interstitial lung diseases. A significant proportion of patients with interstitial lung disease (ILD) manifest autoimmune features consisting, among others, of a morphologic domain with multi-compartment involvement and specific autoantibodies, as well as association to other autoimmune pathologies, such as systemic lupus erythematous, rheumatoid arthritis and Hashimoto thyroiditis. The symptoms of non-specific interstitial include insidious onset of dyspnea and dry cough with a restrictive pattern of decreased lung function and reduced gas exchange capacity. Corticosteroids, anti-fibrotics and immunosuppressants are the classical protocol to treat the condition, but management should be carefully individualized due to the wide heterogeneity of IPAF and lack of evidence in this particular subgroup of patients. The multidisciplinary immunological approach with xenogeneic and/or autologous peptides and its derived immune extracts might be a way to induce autoimmune tolerance, based on the anergy mechanism of secretion of immunomodulatory cytokines, such as IL-10 and transforming growth factor- β (TGF- β ) and T-regulatory cells. Here we report a clinical case of 47 years old woman with IPAF and organized pneumonia (OP) with rheumatic complications addressed integrativelly with the autologous Active Specific Immunotherapy (ASI), xenogeneic peptide immunotherapy, ozone autohemotherapy and nutritional antioxidants perfusion. The integrative biomedical program was run from July 2019 until February 2020 with stabilization of lung degeneration and compliances, consequent modulation of chronic inflammation, progressive reduction of dry cough and joint pain, less fatigue, better sleep quality, overall energy and further decreasing of pharmaceutical’s dosage. This article opens a scientific discussion on how to address positively to chronic autoimmune conditions within the use of biomedical multifunctional and natural tools like autologous and xenogeneic immunotherapy in combination with a more conservative pharmaceutical protocol.
{"title":"Integration of active specific immunotherapy and cell therapy into the protocols of biomedical management of interstitial pneumonia with autoimmune features – A case study","authors":"R. Moya, Mike K. S. Chan, M. Wong, D. Klokol","doi":"10.15761/CMR.1000158","DOIUrl":"https://doi.org/10.15761/CMR.1000158","url":null,"abstract":"Non-specific interstitial pneumonia (NSIP) is the second most common morphological and pathological pattern of interstitial lung diseases. A significant proportion of patients with interstitial lung disease (ILD) manifest autoimmune features consisting, among others, of a morphologic domain with multi-compartment involvement and specific autoantibodies, as well as association to other autoimmune pathologies, such as systemic lupus erythematous, rheumatoid arthritis and Hashimoto thyroiditis. The symptoms of non-specific interstitial include insidious onset of dyspnea and dry cough with a restrictive pattern of decreased lung function and reduced gas exchange capacity. Corticosteroids, anti-fibrotics and immunosuppressants are the classical protocol to treat the condition, but management should be carefully individualized due to the wide heterogeneity of IPAF and lack of evidence in this particular subgroup of patients. The multidisciplinary immunological approach with xenogeneic and/or autologous peptides and its derived immune extracts might be a way to induce autoimmune tolerance, based on the anergy mechanism of secretion of immunomodulatory cytokines, such as IL-10 and transforming growth factor- β (TGF- β ) and T-regulatory cells. Here we report a clinical case of 47 years old woman with IPAF and organized pneumonia (OP) with rheumatic complications addressed integrativelly with the autologous Active Specific Immunotherapy (ASI), xenogeneic peptide immunotherapy, ozone autohemotherapy and nutritional antioxidants perfusion. The integrative biomedical program was run from July 2019 until February 2020 with stabilization of lung degeneration and compliances, consequent modulation of chronic inflammation, progressive reduction of dry cough and joint pain, less fatigue, better sleep quality, overall energy and further decreasing of pharmaceutical’s dosage. This article opens a scientific discussion on how to address positively to chronic autoimmune conditions within the use of biomedical multifunctional and natural tools like autologous and xenogeneic immunotherapy in combination with a more conservative pharmaceutical protocol.","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73832753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders in children. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD will have trouble paying attention, controlling impulsive behaviors, or be overly active. The hallmarks are hyperactivity, impulsivity, and inattention that are beyond reasonable developmental expectations for a child's age. The science behind Brillia is based on a new way to combine homeopathy and antibody science. The active ingredient of Brillia, Lapine S-100 immune globulin, is produced using antibodies to the brainspecific S-100 protein (S-100B). This protein is an essential regulator of many different intracellular and extracellular brain processes, e.g., various enzyme activities, calcium homeostasis, communication between neurons, etc. Thus, the clinical study of the efficacy of Brillia for Children for the treatment of anxiety disorders, disturbances of behavior, and attention, accompanied by increased excitability, irritability, and hyperactivity, are very important and promising. To determine the efficacy of Brillia for Children for the treatment of anxiety disorders, disturbances of behavior, and attention, accompanied by increased excitability, irritability, and hyperactivity in children, two clinical studies were carried out. Methods: A double-blind, randomized placebo-controlled study of Brillia evaluating clinical efficacy and safety for children with attention deficit hyperactivity disorder was conducted. Prior to inclusion in the study, the patients or their legal guardians were provided with information about the study and signed an informed consent form. Patient information collected during the study is strictly confidential. *Correspondence to: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com
背景:注意缺陷/多动障碍(ADHD)是儿童最常见的神经发育障碍之一。它通常在儿童时期首次被诊断出来，通常持续到成年。患有多动症的儿童很难集中注意力、控制冲动行为或过于活跃。其特征是多动、冲动和注意力不集中，超出了儿童年龄的合理发展预期。Brillia背后的科学是基于一种结合顺势疗法和抗体科学的新方法。宝莲的有效成分，Lapine S-100免疫球蛋白，是使用大脑特异性S-100蛋白(S-100B)的抗体产生的。该蛋白是许多不同的细胞内和细胞外脑过程的重要调节因子，例如各种酶活性，钙稳态，神经元之间的通信等。因此，对小儿布里安治疗焦虑症、行为障碍、注意力障碍、伴兴奋性增加、易怒和多动的临床研究是非常重要和有希望的。为了确定brilliant for Children治疗儿童焦虑症、行为障碍和注意力障碍，并伴有易兴奋、易怒和多动症的疗效，进行了两项临床研究。方法:采用双盲、随机、安慰剂对照研究，评价Brillia治疗儿童注意缺陷多动障碍的临床疗效和安全性。在纳入研究之前，向患者或其法定监护人提供了有关研究的信息，并签署了知情同意书。在研究期间收集的患者信息是严格保密的。*通讯:Timothy Allen, Global Allied Pharmaceuticals，卓越研发中心，160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com
{"title":"Clinical and safety evaluation of Brillia patients with Attention-Deficit/Hyperactivity Disorder","authors":"T. Allen, Rashash Dhoalokia, Sylvia Johnson-Park, Giridhar Mnv, Naveed Basha Court","doi":"10.15761/cmr.1000155","DOIUrl":"https://doi.org/10.15761/cmr.1000155","url":null,"abstract":"Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders in children. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD will have trouble paying attention, controlling impulsive behaviors, or be overly active. The hallmarks are hyperactivity, impulsivity, and inattention that are beyond reasonable developmental expectations for a child's age. The science behind Brillia is based on a new way to combine homeopathy and antibody science. The active ingredient of Brillia, Lapine S-100 immune globulin, is produced using antibodies to the brainspecific S-100 protein (S-100B). This protein is an essential regulator of many different intracellular and extracellular brain processes, e.g., various enzyme activities, calcium homeostasis, communication between neurons, etc. Thus, the clinical study of the efficacy of Brillia for Children for the treatment of anxiety disorders, disturbances of behavior, and attention, accompanied by increased excitability, irritability, and hyperactivity, are very important and promising. To determine the efficacy of Brillia for Children for the treatment of anxiety disorders, disturbances of behavior, and attention, accompanied by increased excitability, irritability, and hyperactivity in children, two clinical studies were carried out. Methods: A double-blind, randomized placebo-controlled study of Brillia evaluating clinical efficacy and safety for children with attention deficit hyperactivity disorder was conducted. Prior to inclusion in the study, the patients or their legal guardians were provided with information about the study and signed an informed consent form. Patient information collected during the study is strictly confidential. *Correspondence to: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84605365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Preclinical and preliminary clinical reports for successful treatment of ovarian cancer with standard treatments in combination with epigenetic modifiers in a complimentary and integrative approach","authors":"M. Nezami, J. Garner","doi":"10.15761/cmr.1000143","DOIUrl":"https://doi.org/10.15761/cmr.1000143","url":null,"abstract":"","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85063999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Allen, Rashash Dhoalokia, Sylvia Johnson- Park, Giridhar Mnv, Naveed Basha Court
Background: According to the American Psychiatric Association, anxiety disorders are the most common type of psychiatric disorder. Many patients with anxiety disorders experience physical symptoms related to anxiety and subsequently visit their primary care providers instead of psychiatrists. Despite the high prevalence rates of these anxiety disorders, they often are under-recognized and undertreated clinical problems. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), anxiety disorders include disorders that share features of excessive fear, anxiety and related behavioral disturbances. These disorders include separation anxiety disorder, selective autism, specific phobia, social anxiety disorder (social phobia), panic disorder, agoraphobia, generalized anxiety disorder, substance/medication-induced anxiety disorder, and anxiety disorder due to another medical condition. Brillia uses the combined sciences of homeopathy and antibodies, which is a new way of treatment. The active ingredient of Brillia, Lapine S-100 immune globulin, is produced using antibodies to the brain-specific S-100 protein (S-100B), which acts as an essential regulator for many different intracellular and extracellular brain processes. To establish the clinical efficacy of Brillia for the treatment of anxiety disorders, the conduct of clinical study was relevant. Thus, to determine the efficacy and safety of Brillia for the treatment of anxiety disorders and Attention-Deficit/Hyperactivity Disorders, two clinical studies were designed for each indication. One such clinical research on the patients with anxiety disorders is explained in this article, and results from the other clinical study on the patients with Attention-Deficit/Hyperactivity Disorder is described in another publication/section. Methods: A double-blind placebo-controlled randomized study of Brillia evaluating clinical efficacy and safety for children with anxiety disorders. Before the patients were recruited in the study, the patients of the legal guardians of the patient were explained about the study and signed informed consent was received. Any patientrelated information that was collected during the conduct of the research is handled confidentially. Prior to inclusion in the study, the patients or their legal guardians were provided with information about the study and signed an informed consent form. Patient information collected during the study is strictly confidential. *Correspondence to: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com
背景:根据美国精神病学协会，焦虑症是最常见的精神障碍类型。许多患有焦虑症的患者经历了与焦虑相关的身体症状，随后去看他们的初级保健提供者，而不是精神科医生。尽管这些焦虑症的患病率很高，但它们往往是未得到充分认识和治疗的临床问题。根据《精神疾病诊断与统计手册》第五版(DSM-V)，焦虑症包括具有过度恐惧、焦虑和相关行为障碍特征的疾病。这些障碍包括分离焦虑障碍、选择性自闭症、特定恐惧症、社交焦虑障碍(社交恐惧症)、恐慌障碍、广场恐怖症、广泛性焦虑障碍、物质/药物引起的焦虑障碍和由另一种疾病引起的焦虑障碍。Brillia将顺势疗法和抗体结合起来，这是一种新的治疗方法。Brillia的活性成分，Lapine S-100免疫球蛋白，是使用针对脑特异性S-100蛋白(S-100B)的抗体产生的，该蛋白在许多不同的细胞内和细胞外脑过程中起着重要的调节作用。为确定布里安治疗焦虑障碍的临床疗效，开展相关临床研究。因此，为了确定Brillia治疗焦虑症和注意力缺陷/多动障碍的有效性和安全性，针对每种适应症设计了两项临床研究。这篇文章解释了一项关于焦虑症患者的临床研究，另一篇关于注意力缺陷/多动障碍患者的临床研究结果在另一篇出版物/章节中描述。方法:采用双盲、安慰剂对照、随机对照的方法，评价布里安治疗儿童焦虑症的临床疗效和安全性。在纳入研究前，向患者的法定监护人的患者解释了研究的情况，并签署了知情同意书。在研究过程中收集的任何与患者相关的信息都将保密处理。在纳入研究之前，向患者或其法定监护人提供了有关研究的信息，并签署了知情同意书。在研究期间收集的患者信息是严格保密的。*通讯:Timothy Allen, Global Allied Pharmaceuticals，卓越研发中心，160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com
{"title":"Clinical and safety evaluation of Brillia in patients with Anxiety Disorder","authors":"T. Allen, Rashash Dhoalokia, Sylvia Johnson- Park, Giridhar Mnv, Naveed Basha Court","doi":"10.15761/cmr.1000154","DOIUrl":"https://doi.org/10.15761/cmr.1000154","url":null,"abstract":"Background: According to the American Psychiatric Association, anxiety disorders are the most common type of psychiatric disorder. Many patients with anxiety disorders experience physical symptoms related to anxiety and subsequently visit their primary care providers instead of psychiatrists. Despite the high prevalence rates of these anxiety disorders, they often are under-recognized and undertreated clinical problems. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), anxiety disorders include disorders that share features of excessive fear, anxiety and related behavioral disturbances. These disorders include separation anxiety disorder, selective autism, specific phobia, social anxiety disorder (social phobia), panic disorder, agoraphobia, generalized anxiety disorder, substance/medication-induced anxiety disorder, and anxiety disorder due to another medical condition. Brillia uses the combined sciences of homeopathy and antibodies, which is a new way of treatment. The active ingredient of Brillia, Lapine S-100 immune globulin, is produced using antibodies to the brain-specific S-100 protein (S-100B), which acts as an essential regulator for many different intracellular and extracellular brain processes. To establish the clinical efficacy of Brillia for the treatment of anxiety disorders, the conduct of clinical study was relevant. Thus, to determine the efficacy and safety of Brillia for the treatment of anxiety disorders and Attention-Deficit/Hyperactivity Disorders, two clinical studies were designed for each indication. One such clinical research on the patients with anxiety disorders is explained in this article, and results from the other clinical study on the patients with Attention-Deficit/Hyperactivity Disorder is described in another publication/section. Methods: A double-blind placebo-controlled randomized study of Brillia evaluating clinical efficacy and safety for children with anxiety disorders. Before the patients were recruited in the study, the patients of the legal guardians of the patient were explained about the study and signed informed consent was received. Any patientrelated information that was collected during the conduct of the research is handled confidentially. Prior to inclusion in the study, the patients or their legal guardians were provided with information about the study and signed an informed consent form. Patient information collected during the study is strictly confidential. *Correspondence to: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89474410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Invitro and invivo correlation of biomarker response to epigenetic therapy in pancreatic cancer","authors":"M. Nezami","doi":"10.15761/cmr.1000149","DOIUrl":"https://doi.org/10.15761/cmr.1000149","url":null,"abstract":"","PeriodicalId":93173,"journal":{"name":"EC clinical and medical case reports","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88147525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号